A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

On Tuesday night, millions of Americans watched as former president Donald J. Trump gathered up enough electoral votes needed ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...